383 related articles for article (PubMed ID: 18502632)
1. WT1 peptide vaccine for the treatment of cancer.
Oka Y; Tsuboi A; Oji Y; Kawase I; Sugiyama H
Curr Opin Immunol; 2008 Apr; 20(2):211-20. PubMed ID: 18502632
[TBL] [Abstract][Full Text] [Related]
2. [Immunotherapy targeting the Wilms' tumor 1 gene product for patients with malignant brain tumors].
Hashimoto N; Tsuboi A; Chiba Y; Izumoto S; Oka Y; Yoshimine T; Sugiyama H
Brain Nerve; 2009 Jul; 61(7):805-14. PubMed ID: 19618858
[TBL] [Abstract][Full Text] [Related]
3. Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes.
Fujiki F; Oka Y; Tsuboi A; Kawakami M; Kawakatsu M; Nakajima H; Elisseeva OA; Harada Y; Ito K; Li Z; Tatsumi N; Sakaguchi N; Fujioka T; Masuda T; Yasukawa M; Udaka K; Kawase I; Oji Y; Sugiyama H
J Immunother; 2007 Apr; 30(3):282-93. PubMed ID: 17414319
[TBL] [Abstract][Full Text] [Related]
4. Cancer immunotherapy targeting Wilms' tumor gene WT1 product.
Sugiyama H
Expert Rev Vaccines; 2005 Aug; 4(4):503-12. PubMed ID: 16117707
[TBL] [Abstract][Full Text] [Related]
5. WT1 peptide cancer vaccine for patients with hematopoietic malignancies and solid cancers.
Oka Y; Tsuboi A; Elisseeva OA; Nakajima H; Fujiki F; Kawakami M; Shirakata T; Nishida S; Hosen N; Oji Y; Kawase I; Sugiyama H
ScientificWorldJournal; 2007 May; 7():649-65. PubMed ID: 17619750
[TBL] [Abstract][Full Text] [Related]
6. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
[TBL] [Abstract][Full Text] [Related]
7. Development of WT1 peptide cancer vaccine against hematopoietic malignancies and solid cancers.
Oka Y; Tsuboi A; Kawakami M; Elisseeva OA; Nakajima H; Udaka K; Kawase I; Oji Y; Sugiyama H
Curr Med Chem; 2006; 13(20):2345-52. PubMed ID: 16918359
[TBL] [Abstract][Full Text] [Related]
8. [Immunotherapy for leukemia cells by using cytotoxic T lymphocyte specifically against WT1-derived peptide: an experimental study in vitro].
Gu WY; Cao XS; Qiu GQ; Chen ZX; Sheng LX; Xie XB; He J; Cen JN; Shen HL
Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(49):3475-80. PubMed ID: 16686063
[TBL] [Abstract][Full Text] [Related]
9. WT1 peptide vaccine as a paradigm for "cancer antigen-derived peptide"-based immunotherapy for malignancies: successful induction of anti-cancer effect by vaccination with a single kind of WT1 peptide.
Oka Y; Tsuboi A; Fujiki F; Li Z; Nakajima H; Hosen N; Shirakata T; Nishida S; Oji Y; Kawase I; Sugiyama H
Anticancer Agents Med Chem; 2009 Sep; 9(7):787-97. PubMed ID: 19538172
[TBL] [Abstract][Full Text] [Related]
10. Enhanced tumor immunity of WT1 peptide vaccination by interferon-β administration.
Nakajima H; Oka Y; Tsuboi A; Tatsumi N; Yamamoto Y; Fujiki F; Li Z; Murao A; Morimoto S; Hosen N; Shirakata T; Nishida S; Kawase I; Isaka Y; Oji Y; Sugiyama H
Vaccine; 2012 Jan; 30(4):722-9. PubMed ID: 22133512
[TBL] [Abstract][Full Text] [Related]
11. Identification of a highly immunogenic HLA-A*01-binding T cell epitope of WT1.
Asemissen AM; Keilholz U; Tenzer S; Müller M; Walter S; Stevanovic S; Schild H; Letsch A; Thiel E; Rammensee HG; Scheibenbogen C
Clin Cancer Res; 2006 Dec; 12(24):7476-82. PubMed ID: 17189421
[TBL] [Abstract][Full Text] [Related]
12. WT1 (Wilms' tumor gene 1): biology and cancer immunotherapy.
Sugiyama H
Jpn J Clin Oncol; 2010 May; 40(5):377-87. PubMed ID: 20395243
[TBL] [Abstract][Full Text] [Related]
13. Identification of a WT1 protein-derived peptide, WT1, as a HLA-A 0206-restricted, WT1-specific CTL epitope.
Li Z; Oka Y; Tsuboi A; Fujiki F; Harada Y; Nakajima H; Masuda T; Fukuda Y; Kawakatsu M; Morimoto S; Katagiri T; Tatsumi N; Hosen N; Shirakata T; Nishida S; Kawakami Y; Udaka K; Kawase I; Oji Y; Sugiyama H
Microbiol Immunol; 2008 Nov; 52(11):551-8. PubMed ID: 19090835
[TBL] [Abstract][Full Text] [Related]
14. [Cancer antigen WT1-targeting treatment for the malignancies].
Oka Y; Kawase I
Nihon Rinsho Meneki Gakkai Kaishi; 2008 Oct; 31(5):375-82. PubMed ID: 18974621
[TBL] [Abstract][Full Text] [Related]
15. [Elimination of leukemic CD34+ progenitor cells by using cytotoxic T lymphocytes specifically targeting WT1-derived peptide: an experimental study in vitro].
Gu WY; Chen ZX; Qiu GQ; Hu SY; Jia L; Wu W; He J; Cen JN; He B
Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(48):3401-6. PubMed ID: 19159569
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapeutic targeting of Wilms' tumor protein.
Hutchings Y; Osada T; Woo CY; Clay TM; Lyerly HK; Morse MA
Curr Opin Mol Ther; 2007 Feb; 9(1):62-9. PubMed ID: 17330403
[TBL] [Abstract][Full Text] [Related]
17. Vaccination with a recombinant protein encoding the tumor-specific antigen NY-ESO-1 elicits an A2/157-165-specific CTL repertoire structurally distinct and of reduced tumor reactivity than that elicited by spontaneous immune responses to NY-ESO-1-expressing Tumors.
Bioley G; Guillaume P; Luescher I; Bhardwaj N; Mears G; Old L; Valmori D; Ayyoub M
J Immunother; 2009; 32(2):161-8. PubMed ID: 19238015
[TBL] [Abstract][Full Text] [Related]
18. Immunological response after therapeutic vaccination with WT1 mRNA-loaded dendritic cells in end-stage endometrial carcinoma.
Coosemans A; Wölfl M; Berneman ZN; Van Tendeloo V; Vergote I; Amant F; Van Gool SW
Anticancer Res; 2010 Sep; 30(9):3709-14. PubMed ID: 20944158
[TBL] [Abstract][Full Text] [Related]
19. Antilung cancer effect of WT1-specific cytotoxic T lymphocytes.
Makita M; Hiraki A; Azuma T; Tsuboi A; Oka Y; Sugiyama H; Fujita S; Tanimoto M; Harada M; Yasukawa M
Clin Cancer Res; 2002 Aug; 8(8):2626-31. PubMed ID: 12171894
[TBL] [Abstract][Full Text] [Related]
20. A clear correlation between WT1-specific Th response and clinical response in WT1 CTL epitope vaccination.
Fujiki F; Oka Y; Kawakatsu M; Tsuboi A; Tanaka-Harada Y; Hosen N; Nishida S; Shirakata T; Nakajima H; Tatsumi N; Hashimoto N; Taguchi T; Ueda S; Nonomura N; Takeda Y; Ito T; Myoui A; Izumoto S; Maruno M; Yoshimine T; Noguchi S; Okuyama A; Kawase I; Oji Y; Sugiyama H
Anticancer Res; 2010 Jun; 30(6):2247-54. PubMed ID: 20651376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]